Association Between Corticosteroid Exposure and Immunotherapy Outcome Identified
Patients with lung cancer who were treated with immune checkpoint inhibitors had worse outcomes if they received corticosteroids for palliative indications.
Non-Small Cell Lung Cancer
Efficacy of Maintenance Therapy After Induction Therapy in Patients With Nonsquamous NSCLC and Wild-Type EGFR
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
Cardiac Radiation Dose in NSCLC Predicts Mortality, Cardiac AEs
Cardiac radiation dose exposure is a modifiable cardiac risk factor for major adverse cardiac events (MACE) and all-cause mortality (ACM) in patients with non-small cell lung cancer (NSCLC).
EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy Versus Gefitinib Alone
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
Phase 2 Data Suggest Enhanced Benefit of Combination ICI as Preoperative Treatment in Nonmetastatic NSCLC
In this study, higher levels of tumor PD-L1 expression correlated with higher responses to neoadjuvant immune checkpoint inhibitor-based therapy.
No Improvement in Clinical Outcome With Addition of Metformin to Curative Chemoradiation Therapy in Locally Advanced NSCLC
The addition of metformin to curative chemoradiation therapy was well tolerated in patients with unresected stage IIIA/B NSCLC.
Men and Women May Respond Differently to Immunotherapy for NSCLC
Meta-analyses showed women appear to benefit more from treatment with a combination regimen consisting of a PD-1 inhibitor plus chemotherapy than men.
Checkpoint Inhibitor Efficacy in NSCLC Varied Depending on Type of Molecular Alterations Present
Patients with actionable molecular aberrations should be administered chemotherapy or targeted therapies prior to trying immunotherapies, researchers asserted.
Linking EHR and Genomic Data to Evaluate Patterns of Care
Linking EHRs with genomic profiling data from patients with NSCLC supported associations seen in clinical trials.
Next post in Lung Cancer
